AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$SKYE

Schwab Andrew J. sold $240K of SKYE (indirect holdings)

Schwab Andrew J. sold 148,079 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $1.62 ($1.61–$1.65, $0.24M total) across 4 trades over 2026-09-22 to 2026-09-23.

Original reporting
SEC EDGAR · Schwab Andrew J.
Published Sep 24, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SKYE
Bearish
medium confidence
Mentioned
$SKYE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYEBearishLow
01

Why it matters

Direct insider sale provides fresh data; limited materiality due to small amount.

02

Market read

First-report insider sale; modest negative signal but low trading impact.

03

What to watch

Potential tax planning or liquidity needs for the director; not necessarily a red flag.

Relevance 4/10Novelty 5/10Timing: filing date 2026-09-24

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$SKYEBearishMedium confidence
Context

Director Andrew J. Schwab sold 148,079 shares for $239.6K, reducing his stake to zero.

Expected impact

Potential short-term dip of 1-2% as market digests the sale.

Evidence & confidence

Sale size is modest ($240K) and represents a complete exit, but director exits are not uncommon and may not drive large moves.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals; price may remain stable.

Key entities

  • Company
    Skye Bioscience, Inc.

    Biotech firm listed under ticker SKYE.

  • Insider
    Andrew J. Schwab

    Director and 10% owner of Skye Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SKYE insider trading history →

Related articles

AUG 17
$SKYEMedAI 8/10

Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up

Skye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.

rttnews.com4 min
AUG 14
$SKYEHighAI 9/10

Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.

finanznachrichten.de4 min